Atomwise
The AI engine Fit Assessment
BetaAtomwise is a preclinical pharmaceutical company that utilizes artificial intelligence to enhance the drug discovery process. Their proprietary technology, AtomNet®, focuses on identifying and optimizing small-molecule drug candidates for various disease targets.
Blurb
Atomwise develops artificial intelligence systems using powerful deep learning algorithms and supercomputers for drug discovery.
HQ Location
San Francisco (United States)
Founded
2012
Employees
51 - 200
Total funding raised
$176.65M
Last Funding Event
Grant, $2.30M, October 6, 2020
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Drug Discovery Optimization
Operator of an artificial intelligence-based biotechnology company intended to help invent new potential medicines for disease targets. The company's technology helps in drug hit discovery, binding affinity prediction, and toxicity detection, enabling scientists to discover small molecules for the treatment and investigation of human diseases.